Liquid biopsy: a step forward towards precision medicine in urologic malignancies
Abstract There is a growing trend towards exploring the use of a minimally invasive “liquid biopsy” to identify biomarkers in a number of cancers, including urologic malignancies. Multiple aspects can be assessed in circulating cell-free DNA, including cell-free DNA levels, integrity, methylation an...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-04-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12943-017-0644-5 |
| _version_ | 1811263648369213440 |
|---|---|
| author | Ashley Di Meo Jenni Bartlett Yufeng Cheng Maria D. Pasic George M. Yousef |
| author_facet | Ashley Di Meo Jenni Bartlett Yufeng Cheng Maria D. Pasic George M. Yousef |
| author_sort | Ashley Di Meo |
| collection | DOAJ |
| description | Abstract There is a growing trend towards exploring the use of a minimally invasive “liquid biopsy” to identify biomarkers in a number of cancers, including urologic malignancies. Multiple aspects can be assessed in circulating cell-free DNA, including cell-free DNA levels, integrity, methylation and mutations. Other prospective liquid biopsy markers include circulating tumor cells, circulating RNAs (miRNA, lncRNAs and mRNAs), cell-free proteins, peptides and exosomes have also emerged as non-invasive cancer biomarkers. These circulating molecules can be detected in various biological fluids, including blood, urine, saliva and seminal plasma. Liquid biopsies hold great promise for personalized medicine due to their ability to provide multiple non-invasive global snapshots of the primary and metastatic tumors. Molecular profiling of circulating molecules has been a stepping-stone to the successful introduction of several non-invasive multi-marker tests into the clinic. In this review, we provide an overview of the current state of cell-free DNA-based kidney, prostate and bladder cancer biomarker research and discuss the potential utility other circulating molecules. We will also discuss the challenges and limitations facing non-invasive cancer biomarker discovery and the benefits of this growing area of translational research. |
| first_indexed | 2024-04-12T19:49:09Z |
| format | Article |
| id | doaj.art-d145ef23afec4cb98902eeab2b5cf5fa |
| institution | Directory Open Access Journal |
| issn | 1476-4598 |
| language | English |
| last_indexed | 2024-04-12T19:49:09Z |
| publishDate | 2017-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj.art-d145ef23afec4cb98902eeab2b5cf5fa2022-12-22T03:18:53ZengBMCMolecular Cancer1476-45982017-04-0116111410.1186/s12943-017-0644-5Liquid biopsy: a step forward towards precision medicine in urologic malignanciesAshley Di Meo0Jenni Bartlett1Yufeng Cheng2Maria D. Pasic3George M. Yousef4Department of Laboratory Medicine and Pathobiology, University of TorontoDepartment of Laboratory Medicine and Pathobiology, University of TorontoDepartment of Radiation Oncology, Qilu Hospital of Shandong UniversityDepartment of Laboratory Medicine and Pathobiology, University of TorontoDepartment of Laboratory Medicine and Pathobiology, University of TorontoAbstract There is a growing trend towards exploring the use of a minimally invasive “liquid biopsy” to identify biomarkers in a number of cancers, including urologic malignancies. Multiple aspects can be assessed in circulating cell-free DNA, including cell-free DNA levels, integrity, methylation and mutations. Other prospective liquid biopsy markers include circulating tumor cells, circulating RNAs (miRNA, lncRNAs and mRNAs), cell-free proteins, peptides and exosomes have also emerged as non-invasive cancer biomarkers. These circulating molecules can be detected in various biological fluids, including blood, urine, saliva and seminal plasma. Liquid biopsies hold great promise for personalized medicine due to their ability to provide multiple non-invasive global snapshots of the primary and metastatic tumors. Molecular profiling of circulating molecules has been a stepping-stone to the successful introduction of several non-invasive multi-marker tests into the clinic. In this review, we provide an overview of the current state of cell-free DNA-based kidney, prostate and bladder cancer biomarker research and discuss the potential utility other circulating molecules. We will also discuss the challenges and limitations facing non-invasive cancer biomarker discovery and the benefits of this growing area of translational research.http://link.springer.com/article/10.1186/s12943-017-0644-5Precision medicinePersonalized medicineKidney cancerBladder cancerProstate cancerLiquid biopsy |
| spellingShingle | Ashley Di Meo Jenni Bartlett Yufeng Cheng Maria D. Pasic George M. Yousef Liquid biopsy: a step forward towards precision medicine in urologic malignancies Molecular Cancer Precision medicine Personalized medicine Kidney cancer Bladder cancer Prostate cancer Liquid biopsy |
| title | Liquid biopsy: a step forward towards precision medicine in urologic malignancies |
| title_full | Liquid biopsy: a step forward towards precision medicine in urologic malignancies |
| title_fullStr | Liquid biopsy: a step forward towards precision medicine in urologic malignancies |
| title_full_unstemmed | Liquid biopsy: a step forward towards precision medicine in urologic malignancies |
| title_short | Liquid biopsy: a step forward towards precision medicine in urologic malignancies |
| title_sort | liquid biopsy a step forward towards precision medicine in urologic malignancies |
| topic | Precision medicine Personalized medicine Kidney cancer Bladder cancer Prostate cancer Liquid biopsy |
| url | http://link.springer.com/article/10.1186/s12943-017-0644-5 |
| work_keys_str_mv | AT ashleydimeo liquidbiopsyastepforwardtowardsprecisionmedicineinurologicmalignancies AT jennibartlett liquidbiopsyastepforwardtowardsprecisionmedicineinurologicmalignancies AT yufengcheng liquidbiopsyastepforwardtowardsprecisionmedicineinurologicmalignancies AT mariadpasic liquidbiopsyastepforwardtowardsprecisionmedicineinurologicmalignancies AT georgemyousef liquidbiopsyastepforwardtowardsprecisionmedicineinurologicmalignancies |